2003-06-24
Drug-eluting stents: cost versus clinical benefit.
Publication
Publication
Circulation (Baltimore) , Volume 107 - Issue 24 p. 3003- 3007
The publication in January 2001 of the first-in-man results showing zero restenosis after sirolimus-eluting stent implantation produced enormous excitement in the cardiological community. The long-awaited tool—a safe, restenosis-proof, easy-to-use stent— had been found. It was not too long thereafter that paclitaxel-eluting stents also demonstrated their capability to decrease restenosis.
Additional Metadata | |
---|---|
, , , , , , , | |
doi.org/10.1161/01.CIR.0000078025.19258.28, hdl.handle.net/1765/13173 | |
Circulation (Baltimore) | |
Organisation | Erasmus MC: University Medical Center Rotterdam |
Lemos Neto, P., Serruys, P., & Sousa, E. (2003). Drug-eluting stents: cost versus clinical benefit. Circulation (Baltimore), 107(24), 3003–3007. doi:10.1161/01.CIR.0000078025.19258.28 |